We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Without the credit’s lowering of development costs over the past 30 years, the number of orphan drugs produced in the U.S. would have dropped by one-third. Read More
A CAPA report showed manufacturing errors that led to many low patient results were caused by a failure to update manufacturing procedures after a design change, the agency said. Read More